Keywords: melphalan, acute toxicity, rats, LD50


Introduction. Bone marrow suppression and gastro-intestinal toxicity are the main limiting factors for treatment of oncological patients and may cause its delaying and disruption. So, search of new effective drugs, biomaterials and substances to ameliorate side effects of anticancer chemotherapy remains actual problem. To study their protective capacity and for preclinical study we require the relevant animal model. It is known that alkylating agents possess the most toxic effect on bone marrow and mucus membranes of intestine and have radiomimetic properties.

The aim of the study – screening studies to define the main parameters of acute toxicity of melphalan in rats for further use as an animal model of cytostatic myelodepression for preclinical studies.

Research Methods. Experiments were performed on inbred rats, which were randomized into 4 groups. Melphalan at the dose of 3, 6, 9 and 12 mg/kg was injected one time intravenously into the tail vein. The main acute toxicity indicators, namely median lethal dose LD50, 1/ LD50 – absolute toxicity, LD84/ LD16 – zone of acute toxic effects, 1/( LD50–S) – the total indicator of toxicity and S – function of the inclination angle (lethal doses variability), were measured by Finney method and method offered by V. V. Prozorovskyi using software StatPlus 2009 Professional 5.8.4.

Results and Discussion. According to the regression analysis by Finney method LD50 is (4.22±0.62) mg/kg (lower limit LD50 – 3.10 mg/kg, higher limit – 5.49 mg/kg). Indicator of LD50 is (4.765±1.003) mg/kg (from 2.63 to 6.90 mg/kg) according to the method proposed by Prozorovskyi in single intravenous injection.

Conclusions. The dose of 3 mg/kg of melphalan was as a single intravenous injection was chosen for further experiments and as a model of cytostatic myelodepression for preclinical studies.


Shevchuk, O.O., Posokhova, K.A., Sidorenko, A.S., Bardakhivska, K.I., Maslenny, V.M., Yushko, L.A., … Nikolaev, V.G. (2014). The influence of enterosorption on some haematological and biochemical indices of the normal rats after single injection of melphalan. Experimental Oncology, 36 (2), 94-100.

Puyo, S., Montaudon, D., & Pourquier, P. (2014). From old alkylating agents to new minor groove binders. Critical Reviews in Oncology/Hematology, 89 (1), 43-61.

Parkhill, A.L. (2013). Oral mucositis and stomatitis associated with conventional and targeted anticancer therapy. Journal of Pharmacovigilance, 01 (03).

Al-Ansari, S., Zecha, J.A.E.M., Barasch, A., de Lange, J., Rozema, F.R., & Raber-Durlacher, J.E. (2015). Oral mucositis induced by anticancer therapies. Current Oral Health Reports, 2 (4), 202-211. Retrieved from:

Arifa, R.D.N., Paula, T.P. de, Madeira, M.F.M., Lima, R.L., Garcia, Z.M., Ávila, T.V., … Souza, D.G. (2016). The reduction of oxidative stress by nanocomposite Fullerol decreases mucositis severity and reverts leukopenia induced by Irinotecan. Pharmacological Research, 107, 102-110. Retrieved from:

Denduluri, N., Patt, D. A., Wang, Y., Bhor, M., Li, X., Favret, A. M., … Lyman, G. H. (2015). Dose delays, dose reductions, and relative dose intensity in patients with cancer who received adjuvant or neoadjuvant chemotherapy in community oncology practices. JNCCN Journal of the National Comprehensive Cancer Network, 13(11), 1383-1393. Retrieved from: 10.6004/jnccn.2015.0166

Gavioli, E., & Abrams, M. (2017). Prevention of granulocyte-colony stimulating factor (G-CSF) induced bone pain using double histamine blockade. Supportive Care in Cancer, 25 (3), 817-822. Retrieved from:

Volpe, D. A., & Warren, M. K. (2003). Myeloid clonogenic assays for comparison of the in vitro toxicity of alkylating agents. Toxicology in Vitro: An International Journal Published in Association with BIBRA, 17(3), 271-277. Retrieved from:­med/12781205

Prozorovsky, V. B. (1962). Use of method of the smallest squares for probit analysis of lethality curves. Farmakologia i Toksykologia, 23 (1), 115-120 [in Russian].

Prozorovsky, V. B. (2007). Statistical analysis of the results of pharmacological studies. Psikhofarmakologia i Biologicheskaia Narkologia, 7 (3–4), 2090-2120 [in Russian].

Bhatt, V., & Saleem, A. (2004). Drug-Induced Neutropenia – Pathophysiology, Clinical Features, and Management. Annals of Clinical & Laboratory Science, 34 (2), 131–137.

Shevchuk, O.O., Snezhkova, E.A., Bardakhiv­skaya, K. ., & Nikolaev, V.G. (2017). Adsorptive Treatment of Acute Radiation Sickness: Past Achievements and New Prospects. In Hemoperfusion, Plasmaperfusion and Other Clinical Uses of General, Biospecific, Immuno and Leucocyte Adsorbents (pp. 245-256). Retrieved from:

Ehrsson, H., Eksborg, S., Österborg, A., Mell­stedt, H., & Lindfors, A. (1989). Oral melphalan pharmacokinetics – relation to dose in patients with multiple myeloma. Medical Oncology and Tumor Pharmacothe­rapy, 6 (2), 151-154. Retrieved from: 10.1007/BF02985238

Bosanquet, A.G., & Gilby, E.D. (1982). Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma. European Journal of Cancer and Clinical Oncology, 18 (4), 355-362. Retrieved from:

How to Cite
Shevchuk, O. O. (2020). STUDY OF SOME ACUTE TOXICITY INDICATORS OF MELPHALAN IN RATS . Medical and Clinical Chemistry, (4), 113-118.